Results 41 to 50 of about 20,247 (196)

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin, Qiong Li, Xuemei Xu, Yuhan Wu, Yin Zhu, Jieqiong Wu, Yuan Fang, Qiubei Chen, Shuyang Wang, Jiang Yu, Yaping Ye, Hongli Jiao   +11 more
wiley   +1 more source

Renal IGFBP6 Interacts With THBS1 to Drive Renal Cellular Senescence and Fibrosis

Advanced Science, EarlyView.
ABSTRACT Epithelial dedifferentiation and myofibroblast activation are critical drivers of chronic kidney disease (CKD) progression. Elevated levels of IGFBP6 have been linked to decreased renal function in CKD patients, but its precise role and underlying mechanisms remain unclear.
Ju‐tao Yu, Chang‐geng Xu, Xiao‐wei Hu, Run‐run Shan, Jia‐nan Wang, Xiang‐yu Li, Yu‐qing Wang, Yu‐hang Dong, Shen‐Zhuo‐Fan Huang, Shuai Sun, Tian Zhao, Ya‐Xin Ru, Xiao‐yu Shen, Rui Hou, Jian‐min You, Fei Zhang, Chao Li, Jie Wei, Chao Hou, Zhi‐juan Wang, Dan‐feng Zhang, Juan Jin, Jia‐gen Wen, Yu‐jie Liu, Ming‐ming Liu, Xiao‐ming Meng, Wei Wang   +26 more
wiley   +1 more source

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1

mAbs
In contrast to natural antibodies that rely mainly on the heavy chain to establish contacts with their cognate antigen, we have developed a bispecific antibody format in which the light chain (LC) drives antigen binding and specificity.
Pauline Malinge, Xavier Chauchet, Jérémie Bourguignon, Nicolas Bosson, Sébastien Calloud, Tereza Bautzova, Marie Borlet, Mette Laursen, Vinardas Kelpsas, Nadia Rose, Franck Gueneau, Ulla Ravn, Giovanni Magistrelli, Nicolas Fischer   +13 more
doaj   +1 more source

Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint

Journal for ImmunoTherapy of Cancer, 2022
Background The CD47-SIRPα pathway acts as an important myeloid cell immune checkpoint and targeting the CD47/SIRPα axis represents a promising strategy to promote antitumor immunity.
Juan Chen, Gang Chen, Na Li, Yao Chen, Lei Nie, Zhen-Hua Wu, Xiao-Feng Mei, Xiao-Ze Wang, Ting-Ting Guo, Mei-Zhu Jiang, Ji-Teng Wang, Hai-Bin Wang   +11 more
doaj   +1 more source

Deficit of CD47 Results in a Defect of Marginal Zone Dendritic Cells, Blunted Immune Response to Particulate Antigen and Impairment of Skin Dendritic Cell Migration [PDF]

The Journal of Immunology, 2006
Abstract CD47 is a ubiquitously expressed cell surface glycoprotein that associates with integrins and regulates chemotaxis, migration, and activation of leukocytes. CD47 is also a ligand for signal regulatory protein α, a cell surface receptor expressed on monocytes, macrophages, granulocytes, and dendritic cell (DC) subsets that ...
Sven, Hagnerud, Partha Pratim, Manna, Marina, Cella, Asa, Stenberg, William A, Frazier, Marco, Colonna, Per-Arne, Oldenborg   +6 more
openaire   +2 more sources

ProSiteHunter: A Unified Framework for Sequence‐Based Prediction of Protein‐Nucleic Acid and Protein‐Protein Binding Sites

Advanced Science, EarlyView.
This study proposed a unified sequence‐based framework for protein binding site prediction, which adopted a tri‐track semantic multi‐source feature fusion strategy to effectively capture diverse macromolecular interaction sites and further improved the accuracy of antibody‐antigen interaction prediction.
Dongliang Hou, Qihang Zhen, Zexin Lv, Xinyue Cui, Suhui Wang, Minghua Hou, Zhan Zhou, Xiaogen Zhou, Guijun Zhang   +8 more
wiley   +1 more source

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy

Journal for ImmunoTherapy of Cancer, 2022
Background Chimeric antigen receptor (CAR) T cell therapy has been successfully applied in treating lymphoma malignancies, but not in solid tumors. CD47 is highly expressed on tumor cells and its overexpression is believed to inhibit phagocytosis by ...
Bolan Yu, Huanpeng Chen, Yuying Yang, Yuqing Deng, Fengjiao Wei, Qingyu Zhao, Yongqi Liu, Zhonghua Liu, Zhaofeng Huang   +8 more
doaj   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

Data from CD47 Enhances <i>In Vivo</i> Functionality of Artificial Antigen-Presenting Cells

, 2023
<div>Abstract<p><b>Purpose:</b> Artificial antigen-presenting cells, aAPC, have successfully been used to stimulate antigen-specific T-cell responses <i>in vitro</i> as well as <i>in vivo</i>. Although aAPC compare favorably with autologous dendritic cells <i>in vitro</i>, their effect <i ...
Christian Schütz, Jonathan P. Schneck, Mathias Oelke, Andreas Mackensen, Shirin Pasemann, Jerry Fang, Carl Haupt, Juan Carlos Varela, Catherine Bessell, Heiko Bruns   +9 more
openaire   +1 more source

Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy

Advanced Science, EarlyView.
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen, Haoyu You, Hefa Huang, Huihui Chai, Ruize Zhu, Yun Guan, Qisheng Tang, Tianwen Li, Shan Jiang, Houshi Xu, Peng Wang, Yue Wang, Maoyuan Sun, Beining Liu, Zhen Li, Yulai Zeng, Weiqiu Ping, Yanlin Teng, Songlin Yan, Qinghui Li, Long Gu, Tao Sun, Zhifeng Shi   +22 more
wiley   +1 more source